American Society of Hematology

Figure 1.

$Figure 1. Expression and function of CD105 in acute leukemias. (A-B) Representative FACS plots show CD105/endoglin expression in several leukemic cells lines (A) and in primary ALL (n = 5) and AML (n = 4) blasts (B). Primary leukemic blasts were initially gated based on SSC and the expression of CD45, CD34, and/or CD38, CD19, or CD117, as shown in supplemental Figure 1. Percentages represent CD105 expression. (C-E) Leukemia-forming activity of AML blasts based on CD105 expression. (C) FACS plot shows gating strategy for the sorting of CD105+ (red) and CD105− (blue) subfractions from the AML blast population. (D) Presence of hCD45+ cells in the PB of NSG mice that had been injected with CD105+ (red) and CD105− (blue) AML blasts. Leukemia-forming activity was increased in the CD105+ AML blast subfraction. Bars represent average percentage of hCD45, and error bars indicate standard error of the mean (SEM) for each cohort (n = 3 per group). *P < .05 by Student t test. (E) Reduced survival rate in mice injected with CD105+ AML blasts (n = 3). *P < .05 by log-rank test. (F-H) Leukemia-forming activity of ALL blasts based on CD105 expression. (F) FACS plot shows gating strategy for the sorting of CD105+ (red) and CD105− (blue) subfractions from the ALL blast population. (G) Graphic shows expression levels of hCD45+ cells in the PB of NSG mice that had been injected with CD105+ (red) and CD105− (blue) ALL blasts. Leukemia-forming activity was restricted to the CD105+ ALL blast subfraction. Error bars indicate SEM for each experimental group (n = 5). ****P < .0001 by Student t test. (H) Reduced survival rate in mice injected with the CD105+ ALL blasts (n = 5 per group). ** P < .01 by log-rank test. SSC-H, SSC height.$

Expression and function of CD105 in acute leukemias. (A-B) Representative FACS plots show CD105/endoglin expression in several leukemic cells lines (A) and in primary ALL (n = 5) and AML (n = 4) blasts (B). Primary leukemic blasts were initially gated based on SSC and the expression of CD45, CD34, and/or CD38, CD19, or CD117, as shown in supplemental Figure 1. Percentages represent CD105 expression. (C-E) Leukemia-forming activity of AML blasts based on CD105 expression. (C) FACS plot shows gating strategy for the sorting of CD105⁺ (red) and CD105⁻ (blue) subfractions from the AML blast population. (D) Presence of hCD45⁺ cells in the PB of NSG mice that had been injected with CD105⁺ (red) and CD105⁻ (blue) AML blasts. Leukemia-forming activity was increased in the CD105⁺ AML blast subfraction. Bars represent average percentage of hCD45, and error bars indicate standard error of the mean (SEM) for each cohort (n = 3 per group). *P < .05 by Student t test. (E) Reduced survival rate in mice injected with CD105⁺ AML blasts (n = 3). *P < .05 by log-rank test. (F-H) Leukemia-forming activity of ALL blasts based on CD105 expression. (F) FACS plot shows gating strategy for the sorting of CD105⁺ (red) and CD105⁻ (blue) subfractions from the ALL blast population. (G) Graphic shows expression levels of hCD45⁺ cells in the PB of NSG mice that had been injected with CD105⁺ (red) and CD105⁻ (blue) ALL blasts. Leukemia-forming activity was restricted to the CD105⁺ ALL blast subfraction. Error bars indicate SEM for each experimental group (n = 5). ****P < .0001 by Student t test. (H) Reduced survival rate in mice injected with the CD105⁺ ALL blasts (n = 5 per group). ** P < .01 by log-rank test. SSC-H, SSC height.

This Feature Is Available To Subscribers Only